Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: a 5-year follow up.

Source:http://linkedlifedata.com/resource/pubmed/id/17876770

Download in:

View as

General Info

PMID
17876770